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Neuroinflammation, which includes both neuropro-
tective and neurotoxic reactions by activated glial
cells and infiltrated immune cells, is involved in the
pathomechanism of amyotrophic lateral sclerosis
(ALS). However, the cytokines that regulate the
neuroprotective inflammatory response in ALS are
not clear. Here, we identify transforming growth fac-
tor-b1 (TGF-b1), which is upregulated in astrocytes
of murine and human ALS, as a negative regulator
of neuroprotective inflammatory response. We
demonstrate that astrocyte-specific overproduction
of TGF-b1 in SOD1G93A mice accelerates disease
progression in a non-cell-autonomous manner, with
reduced IGF-I production in deactivated microglia
and fewer T cells with an IFN-g-dominant milieu.
Moreover, expression levels of endogenous TGF-b1
in SOD1G93A mice negatively correlate with lifespan.
Furthermore, pharmacological administration of a
TGF-b signaling inhibitor after disease onset extends
survival time of SOD1G93A mice. These findings
indicate that astrocytic TGF-b1 determines disease
progression and is critical to the pathomechanism
of ALS.INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is an adult-onset, fatal neuro-
degenerative disease characterized by the selective loss of
motor neurons. While most cases of ALS are of sporadic etiol-
ogy, 10% of cases are familial ALS among which dominant
mutations in the gene for Cu/Zn superoxide dismutase (SOD1)
are the frequent causes. Mice overexpressing the SOD1 gene592 Cell Reports 11, 592–604, April 28, 2015 ª2015 The Authorswith ALS-linked mutations recapitulate both the clinical and
pathological characteristics of ALS.
Neuroinflammation, characterized by activated astrocytes,
microglia, infiltrated T cells, and the subsequent overproduc-
tion of proinflammatory cytokines and other neurotoxic or pro-
tective molecules, is a pathological hallmark not only of mutant
SOD1 mice but also of ALS patients (Engelhardt et al., 1993).
Along with other researchers, we have demonstrated previously
that the selective reduction of mutant SOD1 expression in
microglia (Beers et al., 2006; Boille´e et al., 2006; Wang et al.,
2009) or astrocytes (Wang et al., 2011; Yamanaka et al.,
2008) significantly extends the survival time of ALS mice. More-
over, elimination of functional T cells from mutant SOD1 mice
shortens the survival time (Beers et al., 2008; Chiu et al.,
2008). Thus, non-neuronal cells, such as astrocytes, microglia,
and T cells, are able to modify the course of disease through a
non-cell-autonomous mechanism within the CNS (Ilieva et al.,
2009; Lasiene and Yamanaka, 2011). On the other hand, the
targeting of single proinflammatory cytokines has been tested
as a treatment for ALS mice; however, the effectiveness of
this strategy remains inconclusive. For example, some studies
showed that deletion of TNF-a or IL-1b has marginal effects
on the survival time of mutant SOD1 mice, while one study
showed extended survival of IL-1b-deficient SOD1G93A mice
(Gowing et al., 2006; Meissner et al., 2010; Nguyen et al.,
2001). In contrast, overexpression of neurotrophic factors,
such as IGF-I and GDNF, extends the survival time of mutant
SOD1 mice (Dodge et al., 2008; Henderson et al., 1994; Kaspar
et al., 2003; Wang et al., 2002). Targeting a single proinflamma-
tory cytokine may not be sufficient to modify disease course,
but instead inducing a neuroprotective environment composed
of glial cells and T cells may be more effective. However, it
has not been elucidated what regulates the neuroprotective
glia/immune response.
Transforming growth factor bs (TGF-bs) are pleiotropic cyto-
kines that have key roles in immune homeostasis (Li et al.,
2006), neurotrophic response (Katsuno et al., 2011), and
microglial development (Butovsky et al., 2014). In mouse
models of Alzheimer’s disease (AD) in which the amyloid pre-
cursor gene is overexpressed, increasing astrocytic TGF-b1
levels or blockade of TGF-b signaling in peripheral macro-
phages is shown to reduce senile plaque formation in the brain
parenchyma (Wyss-Coray et al., 1995, 2001; Town et al.,
2008). In ALS patients, TGF-b1 protein levels are elevated in
the serum, plasma, and cerebrospinal fluid (CSF) (Houi et al.,
2002; I1zecka et al., 2002), and recent studies indicate that
TGF-b signaling is implicated in ALS (Iida et al., 2011; Katsuno
et al., 2011; Phatnani et al., 2013). However, the exact roles of
TGF-b1 in the pathomechanism of ALS have not been
elucidated.
In this study, we found TGF-b1 upregulation in the spinal
cord astrocytes of sporadic ALS patients and ALS mice. By
using SOD1G93A mice with overexpression of TGF-b1 in astro-
cytes and SOD1G37R mice with astrocyte-specific deletion of
mutant gene, we identified astrocytic TGF-b1 negatively regu-
lates neuroprotective inflammatory responses through micro-
glia and T cells and accelerates disease progression of ALS
mice. Moreover, pharmacological administration of TGF-b
signaling inhibitor after disease onset extends the survival of
ALS mice. On the other hand, a defect in canonical TGF-b
signaling in motor neurons was unaffected by exogenous
TGF-b1. These findings indicate that cell-type-specific dysre-
gulation of TGF-b signaling is critical to the pathomechanism
underlying ALS.RESULTS
TGF-b1 Is Upregulated in the Spinal Cord Astrocytes of
SOD1G93A Mice and Sporadic ALS Patients
To explore the role of TGF-b1 in ALS pathogenesis, we examined
expression levels of TGF-b1 mRNA in the spinal cord of mutant
SOD1 mice. We found that, among its different isoforms, TGF-
b1 mRNA level was highly upregulated during disease progres-
sion of SOD1G93Amice (Figure 1A) aswell as themice expressing
othermutantSOD1 genes, SOD1G85R and SOD1G37R (Figure 1B).
Immunoblotting also confirmed that TGF-b1 protein level was
upregulated during disease progression of SOD1G93A mice (Fig-
ure 2B). To further examine the cell types that produce TGF-b1
under an acute inflammatory condition, we examined expression
levels of TGF-b1 in SOD1G93A-bearing primary astrocytes and
microglia induced by lipopolysaccharide (LPS) stimulation, since
these glial cells were implicated to produce TGF-b1 under
various neurological diseases (Flanders et al., 1998). We found
a relatively elevated level of TGF-b1 mRNA in SOD1G93A-primary
astrocytes, but reduced TGF-b1 expression in SOD1G93A-pri-
mary microglia upon LPS stimulation (Figure 1C). Immunofluo-
rescence analysis revealed that TGF-b1 protein expressions in
astrocytes were elevated at end stage compared with onset
and that they were markedly observed compared with ones in
microglia of end-stage SOD1G93A mice (Figure 1D). More impor-
tantly, astrocytic TGF-b1 expression also was elevated in the
spinal ventral horn and lateral column of sporadic ALS patients
compared with control (Figure 1E). These results indicate that
expression levels of endogenous TGF-b1 are upregulated inastrocytes during disease progression of ALSmice and sporadic
ALS patients.
Astrocyte-Specific Overproduction of TGF-b1
Accelerates Disease Progression in SOD1G93A Mice
We next crossed SOD1G93A mice with micemodestly expressing
the bioactive form of porcine TGF-b1 under the control of a glial
fibrillary acidic protein (GFAP) promoter (GFAP-TGF-b1 mice)
(Wyss-Coray et al., 1995) and monitored body weight, rotarod
performance, and survival time. Astrocytic TGF-b1 expression
in GFAP-TGF-b1 mice was confirmed by immunoblots, and total
TGF-b1 protein level was elevated in end-stage SOD1G93A/TGF-
b1 mice compared with SOD1G93A mice (Figures 2A and 2B).
Although the time of disease onset remained unchanged in
SOD1G93A/TGF-b1 double-transgenic mice (Figure 2C), the
mean survival time was unexpectedly shortened by about
10 days (SOD1G93A/TGF-b1: 151.7 ± 10.4 days; SOD1G93A:
161.9 ± 9.5 days) (Figure 2D). SOD1G93A/TGF-b1 mice showed
accelerated disease progression in the late stage (Figure 2E) of
ALS, with faster weight loss (Figure 2F) and a decreased perfor-
mance on the rotarod task (Figure 2G). On the other hand, het-
erozygous GFAP-TGF-b1 mice showed neither motor deficit
nor weight loss with a normal lifespan (Figures 2D, 2F, and
2G). Additionally, analysis of motor axons in cross-sections of
L5 ventral root revealed a trend toward more progressive axonal
degeneration in SOD1G93A/TGF-b1mice compared to SOD1G93A
mice, while L5 motor axons in GFAP-TGF-b1 were not affected
(Figures 2H and 2I). Together, these results suggest that astro-
cyte-specific overproduction of TGF-b1 plays a detrimental
role in the disease progression of SOD1G93A mice.
Dysregulated TGF-b Signaling in Spinal Motor Neurons
of SOD1G93A Mice
To determine whether TGF-b signaling is altered during disease
progression of SOD1G93A and SOD1G93A/TGF-b1 mice, we ex-
amined Smad2, which is phosphorylated following stimulation
of TGF-b signaling and transported to the nucleus (Shi and Mas-
sague´, 2003). High levels of phosphorylated Smad2 (pSmad2)
were observed in motor neuron nuclei of non-transgenic mice;
however, pSmad2 levels in SOD1G93A mice were significantly
decreased from pre-symptomatic stage and rarely observed in
end stage (Figures S1A and S1B). Moreover, the loss of pSmad2
in motor neuron nuclei was not recovered by overexpression of
TGF-b1 in SOD1G93A/TGF-b1 mice (Figures S1A and S1B).
Considering that the expressions of TGF-b receptor type 2
(TGFbR2) and type 1 (TGFbR1) and the level of cytoplasmic
pSmad2 in the lumbar motor neurons of SOD1G93A mice were
preserved (Figures S1A and S1C), nuclear transport of pSmad2
is likely to be defective in spinal motor neurons of SOD1G93A
mice. In contrast, glial nuclear pSmad2 expressions were pre-
served in end-stage SOD1G93A and SOD1G93A/TGF-b1 mice
(Figures S2A and S2B).
Astrocyte-Specific Overproduction of TGF-b1 Reduces
the Levels of T Cell-Related Cytokines and Neurotrophic
Factors in SOD1G93A Mice
To identify the molecules linked to the rapid disease progres-
sion in SOD1G93A/TGF-b1 mice, we performed qRT-PCRCell Reports 11, 592–604, April 28, 2015 ª2015 The Authors 593
Figure 1. TGF-b1 Is Upregulated in Astrocytes in the Spinal Cords of Mutant SOD1 Mice and Sporadic ALS Patients
(A) Mean mRNA levels of TGF-b isoforms in the lumbar spinal cord of SOD1G93A (2M, 2-month-old; 3.5M, 3.5-month-old; 4M, 4-month-old; and ES, end-stage)
mice relative to the ones in 6-month-old non-transgenic (Non-Tg) mice are shown.
(B) Mean TGF-b1 mRNA levels in the lumbar spinal cord of end-stage SOD1G85R (G85R) and SOD1G37R (G37R) mice relative to the ones in age-matched Non-Tg
mice are shown.
(C) Mean mRNA levels of TGF-b1 in SOD1G93A-primary microglia and astrocytes with or without LPS treatment (1 mg/ml) are shown. (A–C) *p < 0.05, **p < 0.01,
***p < 0.001. Error bars denote SEM (n = 3 in A and C and n = 3–5 in B).
(legend continued on next page)
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analyses of the lumbar spinal cord of end-stage SOD1G93A and
SOD1G93A/TGF-b1 mice. We observed significantly decreased
mRNA levels of T cell-related cytokines, IFN-g, and IL-4, in
end-stage SOD1G93A/TGF-b1 mice compared with SOD1G93A
mice (Figures 3A and 3B). Further, mRNA levels of the T helper
2 (Th2) cell-specific transcription factor GATA-3 tended to be
reduced in SOD1G93A/TGF-b1 mice, while ones of the Th1 tran-
scription factor T-bet were unaffected (Table S2). The mRNA
levels of the neurotrophic factors IGF-I and GDNF were
decreased significantly (Figures 3C and 3D) in SOD1G93A/
TGF-b1 mice. We also observed lower mRNA levels of micro-
glia activation marker CD68 in SOD1G93A/TGF-b1 mice
(Figure 3E), while the levels of Iba-1, classically activated (M1)
microglia markers (iNOS, CD86, TNF-a, and IL-1b), and alterna-
tively activated (M2) microglia markers (Arginase1 and CD206)
were unaffected with TGF-b1 overproduction (Figures 3F and
3G; Table S2). Overexpression of TGF-b1 itself reduced expres-
sion levels of IFN-g, IL-4, and GDNF in GFAP-TGF-b1 mice
compared to non-transgenic mice (Figures 3A, 3B, and 3D),
while the levels of others were unaffected. Intriguingly, expres-
sion levels of astrocytic marker GFAP measured by qRT-PCR
(Figure S3A) and immunohistochemistry (Figure S3B) were un-
changed during the disease progression between SOD1G93A
and SOD1G93A/TGF-b1. With regard to astrocytic functions,
mRNA levels of S100b, glutamate transporter (GLT-1), and neu-
rocan were not significantly affected (Table S2). The levels of
other glia- or immune-related molecules determined by qRT-
PCR analyses are summarized in Table S2. In summary,
T cell-related cytokines and neurotrophic factors were signifi-
cantly affected by astrocyte-specific overproduction of TGF-
b1 in SOD1G93A mice, while the molecules linked to astrocytic
function were relatively unaffected. Therefore, our next focus
was on the roles of TGF-b1 in microglia and lymphocytes of
SOD1G93A/TGF-b1 mice.Astrocyte-Specific Overproduction of TGF-b1 Inhibits
Microglial Activation and Reduces the Neuroprotective
Properties of Microglia/Macrophages of SOD1G93A Mice
We first investigated the effect of astrocyte-secreted TGF-b1 on
microglial activation in the lumbar spinal cord by immunohisto-
chemistry. We observed that the expression of Mac-2, a marker
for microglial activation, was markedly decreased in the lumbar
ventral horn of SOD1G93A/TGF-b1 compared with SOD1G93A
(Figure 4A, left) mice. Additionally, the number of Mac-2-positive
cells in the ventral horn was significantly decreased in
SOD1G93A/TGF-b1 mice (Figure 4B), although there were no dif-
ferences in expression of the microglial marker Iba-1 (Figure 4A,
right) and the number of Iba-1-positive cells (Figure 4C) between
the two genotypes. These data were in accordance with the(D) Representative images show the ventral horn of the lumbar spinal cord of ons
Mac-2 (blue), along with the merged image. Magnified images of the outlined area
(arrowheads) compared with microglia (arrows). Scale bars, 50 mm.
(E) Representative images show the ventral horn and the lateral column of the cerv
GFAP (red), and DAPI (blue). Note that the signals double-positive for GFAP an
images of the outlined areas (white square) also are shown. Scale bars, 50 mm.
See also Table S1.lower CD68 mRNA levels observed in SOD1G93A/TGF-b1 spinal
cords (Figure 3E).
Moreover, to test whether TGF-b1 directly reduces microglial
activation, morphology and Mac-2 mRNA levels were evaluated
in SOD1G93A-primary microglia cultured in astrocyte-condi-
tioned media (ACM) from SOD1G93A or SOD1G93A/TGF-b1
mice. We found that the sizes of SOD1G93A-primary microglia
cultured with ACM from SOD1G93A/TGF-b1 mice were smaller
than those cultured with ACM from SOD1G93A mice (Figure 4D).
Mac-2 mRNA levels were noticeably reduced in SOD1G93A-pri-
mary microglia with ACM from SOD1G93A/TGF-b1 mice (Fig-
ure 4E). These findings indicate that TGF-b1 directly inhibits
microglial activation. Furthermore, flow cytometric analysis of
spinal microglia from end-stage SOD1G93A and SOD1G93A/
TGF-b1 mice revealed no differences in cell number, cellular
size, granularity (Figures S4A and S4B), surface expression of
CD86 and CD206, and intracellular expression of TNF-a (Fig-
ure S4C) between the two genotypes, indicating no significant
changes in M1 (CD86 and TNF-a) or M2 markers (CD206) in
SOD1G93A microglia by the in vivo expression of TGF-b1.
Having observed a decrease in the mRNA levels of CD68
and IGF-I in the lumbar spinal cord of SOD1G93A/TGF-b1
mice (Figures 3C and 3E), we next evaluated their expression
levels using immunofluorescence. We found that the expres-
sion levels of IGF-I, CD68, CD11c, a dendritic cell marker,
and major histocompatibility complex (MHC) class II were
significantly decreased in microglia of the ventral horn of
SOD1G93A/TGF-b1 mice compared with SOD1G93A mice (Fig-
ure 4F). Moreover, expression of IGF-I in macrophages of the
lumbar ventral root, which was markedly elevated in SOD1G93A
mice, was substantially decreased in SOD1G93A/TGF-b1 mice
(Figure 4G). Expression levels of both CD11c and CD68 in
macrophages of the ventral root were also decreased in
SOD1G93A/TGF-b1 mice compared with SOD1G93A mice (Fig-
ure 4G). In the intact ventral root of non-transgenic mice,
IGF-I- and CD68-positive macrophages were both not detect-
able (Figure 4G). These findings indicate that astrocyte-spe-
cific overproduction of TGF-b1 inhibits activation and neuro-
protective properties of microglia/macrophages in the lumbar
spinal cord.Astrocyte-Specific Overproduction of TGF-b1 Induces
an IFN-g-Dominant Milieu with Reduced Number of
Infiltrated T Cells in SOD1G93A Mice
Our observation of decreasedmRNA levels for IFN-g and IL-4 in
the lumbar spinal cord of SOD1G93A/TGF-b1 mice (Figures 3A
and 3B) led us to evaluate infiltrated CD45hi mononuclear cells
in the spinal cord by flow cytometry. We found that total
numbers of CD4+, CD8+, and CD4CD8 double-negativeet and end-stage SOD1G93A mice stained for TGF-b1 (green), GFAP (red), and
s (white square) also are shown. TGF-b1 expression was elevated in astrocytes
ical spinal cord in sporadic ALS and control patients stained for TGF-b1 (green),
d TGF-b1 were more prominent in ALS spinal cords than controls. Magnified
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Figure 2. Astrocyte-Specific Overproduction of TGF-b1 Accelerates Disease Progression in SOD1G93A Mice
(A and B) Immunoblot analysis for TGF-b1 in (A) primary astrocytes isolated from Non-Tg and GFAP-TGF-b1 mice and in (B) the lumbar spinal cords of Non-Tg,
2-month-old (2M), and end-stage (ES) SOD1G93A (G93A) and SOD1G93A/TGF-b1 (G93A/TGF-b1) mice. GAPDH was used as the internal loading control.
(C and D) Kaplan-Meier curves for (C) onset and plotted mean onset and (D) survival time and plotted mean survival time for G93A (n = 36), G93A/TGF-b1 (n = 33),
and GFAP-TGF-b1 (n = 5) mice are shown.
(E) Plotted durations of early (from onset to 10% weight loss) and late (from 10% weight loss to end stage) stages for G93A and G93A/TGF-b1 mice are shown.
(F) Weekly mean body weight was plotted for GFAP-TGF-b1 (n = 5), G93A (n = 36), and G93A/TGF-b1 (n = 33) mice. (C–F) *p < 0.05, **p < 0.01, ***p < 0.001.
Mean ± SD were plotted.
(G) Rotarod performanceswere evaluatedweekly for GFAP-TGF-b1 (n = 5), G93A (n = 19), andG93A/TGF-b1 (n = 13)mice. Mean holding times on the rotating rod
at indicated ages were plotted.
(H) Images show toluidine blue-stained axial sections of the L5 ventral root of GFAP-TGF-b1 mice and end-stage G93A and G93A/TGF-b1 mice. Scale bars,
50 mm.
(I) The distribution of motor axonal diameters in cross-sections of L5 ventral root of GFAP-TGF-b1 (n = 2), G93A (n = 6), and G93A/TGF-b1 (n = 6) mice were
measured and plotted. *p < 0.05, **p < 0.01. Error bars denote SEM.
See also Figures S1 and S2.(DN) T cells were decreased in SOD1G93A/TGF-b1 mice
compared to SOD1G93A mice, while no significant difference
was observed in the numbers of CD45hiCD3 cells between596 Cell Reports 11, 592–604, April 28, 2015 ª2015 The Authorsthe two genotypes (Figures 5A, 5B, and 5D). We also evaluated
intracellular expression of IFN-g and IL-4 in lymphocytes, and
found that the numbers of IFN-g/IL-4 producing total, CD4+,
Figure 3. Quantitative RT-PCR Analyses of Glia/Immune System-Related Molecules in the Lumbar Spinal Cord of SOD1G93A and SOD1G93A/
TGF-b1 Mice
(A–I) Mean mRNA levels of indicated glia/immune system-related molecules in the lumbar spinal cord of end-stage SOD1G93A (G93A) and SOD1G93A/TGF-b1
(G93A/TGF-b1) mice along with GFAP-TGF-b1 mice relative to the ones from Non-Tg littermates were plotted. Each result was normalized to b-actin. *p < 0.05,
**p < 0.01, ***p < 0.001. Error bars denote SEM (n = 3–5).
See also Table S2 and Figure S3.and DN T cells were significantly decreased in SOD1G93A/TGF-
b1 mice (Figures 5C, 5E, and 5F). Moreover, the ratio of IFN-g/
IL-4 in total and CD4+ T cells was significantly increased in
SOD1G93A/TGF-b1 mice (Figure 5G), indicating that overpro-
duction of TGF-b1 induces an IFN-g-dominant environment
rather than IL-4. On the other hand, there were no significant
differences in the numbers of T cells in the peripheral blood
among all genotypes (Figure 5H). These findings indicate that
astrocyte-specific overproduction of TGF-b1 reduces the num-
ber of infiltrated T cells and induces an IFN-g-dominant milieu in
the spinal cord of SOD1G93A mice.
Astrocyte-Derived TGF-b1 Reduces Neuroprotective
Microglial IGF-I Expression and Dendritic Cell-like
Activation via a Dominant IFN-g-Producing T Cell
Environment
To uncover the mechanism through which astrocyte-derived
TGF-b1 results in a decreased IGF-I expression in microgliaand decreased number of infiltrated T cells with higher ratios
of IFN-g/IL-4-producing T cells in SOD1G93A/TGF-b1 mice,
we performed primary glial and peripheral blood mononuclear
cell (PBMC) co-culture assays using primary glial cells
obtained from non-transgenic, SOD1G93A, and SOD1G93A/
TGF-b1 newborn mice and PBMCs from non-transgenic
and end-stage SOD1G93A mice (Figure 6A). In this assay, we
examined intracellular expression of IGF-I and surface ex-
pressions of CD11c in microglia as well as intracellular expres-
sions of both IFN-g and IL-4 in T cells using flow cytometric
analysis. We found that microglial IGF-I expression was
significantly decreased in the SOD1G93A/TGF-b1-primary
glial cells when cultured with SOD1G93A-PBMC (Figures 6B
and 6C), while IGF-I levels were unaffected without PBMC
(Figure 6C). Additionally, TGF-b1 itself marginally affected
expression levels of IGF-I in microglia (Figures 6C and S5A).
The numbers of T cells as well as IFN-g/IL-4-producing
T cells were significantly reduced when co-cultured withCell Reports 11, 592–604, April 28, 2015 ª2015 The Authors 597
Figure 4. Decreased IGF-I and CD11c Ex-
pressions of Deactivated Microglia/Macro-
phages of SOD1G93A/TGF-b1 Mice
(A) Images show the lumbar spinal cord of end-
stage SOD1G93A (G93A) and SOD1G93A/TGF-b1
(G93A/TGF-b1) mice stained for Mac-2 (left) and
Iba-1 (right). Scale bars, 250 mm.
(B and C) Numbers of (B) Mac-2- and (C) Iba-1-
positive microglia within the ventral horn area from
the lumbar spinal cord of end-stage G93A (blue)
and G93A/TGF-b1 (red) mice are shown. *p < 0.05.
Mean ± SEM were plotted (n = 3).
(D) Images show SOD1G93A primary microglia
cultured with ACM derived from G93A or G93A/
TGF-b1 mice. Scale bars, 50 mm.
(E) Mac-2 mRNA levels of SOD1G93A primary mi-
croglia cultured in the indicated conditions are
shown. **p < 0.01. Mean ± SEM were plotted
(n = 4).
(F) Images show the ventral horn of the lumbar
spinal cord of G93A (top) and G93A/TGF-b1
(bottom)mice stained for IGF-I, CD68, CD11c, and
MHC class II (green) together with Iba-1 (red).
Scale bars, 100 mm.
(G) Images show the lumbar ventral root of end-
stage G93A (left), G93A/TGF-b1 (middle), and
Non-Tg (right) mice stained for IGF-I or CD11c
(green) and CD68 (red). CD68-positive cells in the
ventral root show IGF-I expression (arrowheads).
Scale bars, 100 mm.
See also Figure S4.SOD1G93A/TGF-b1-primary glial cells (Figures 6E–6G). The ra-
tio of IFN-g/IL-4-producing T cells was significantly increased
in the presence of SOD1G93A/TGF-b1-primary glial cells (Fig-
ure 6H). Furthermore, microglial IGF-I expression was nega-
tively correlated with the ratio of IFN-g/IL-4-producing cells
(Figure 6I), and expression of IGF-I in BV-2 microglia was
altered by the IFN-g/IL-4 ratio (Figure S5B). Lastly, microglial
CD11c expression behaved like IGF-I (Figures 6B, 6D, and
6J). These results suggest that astrocyte-derived TGF-b1 re-
duces the neuroprotective properties of microglia, such as
IGF-I expression and dendritic cell-like phenotype, alongside
an IFN-g-dominant milieu of T cells.598 Cell Reports 11, 592–604, April 28, 2015 ª2015 The AuthorsHigher Level of TGF-b1 Is a
Negative Prognostic Factor by
Determining the IFN-g/IL-4 Ratio in
SOD1G93A Mice
We examined the mean mRNA levels
determined by qRT-PCR in the lumbar
spinal cord to evaluate the correlation
among survival time, IFN-g/IL-4 ratio,
and endogenous TGF-b1 levels in
SOD1G93A mice. We found that the sur-
vival time of SOD1G93A mice negatively
correlated not only with TGF-b1 mRNA
level (Figure 7A), but also with the
ratio of IFN-g/IL-4 mRNA (Figure 7B).
Moreover, TGF-b1 levels significantly
correlated with the ratio of IFN-g/IL-4(Figure 7C). In summary, these findings suggest that TGF-b1
is a negative prognostic factor in ALS mice likely through its
determination of IFN-g/IL-4 ratio.
Astrocytic TGF-b1 Is Downregulated in Slowly
Progressive SOD1G37R Mice with Astrocyte-Specific
Deletion of Mutant SOD1
We previously demonstrated that the selective reduction of
mutant SOD1 in astrocytes significantly slowed the disease pro-
gression of loxSOD1G37Rmice usingCre-loxP system (Figure 7D;
Yamanaka et al., 2008). However, astrocyte-derived molecules
that are linked to neurotoxicity have not been fully elucidated.
Figure 5. Decreased Number of Infiltrated T Cells and Increased Ratio of IFN-g/IL-4-Producing T Cells in SOD1G93A/TGF-b1 Mice
Flow cytometric analysis of spinal cord lymphocytes from non-transgenic (Non-Tg), end-stage SOD1G93A (G93A), and SOD1G93A/TGF-b1 (G93A/TGF-b1) mice.
(A–C) Flow cytometric analyses of (A) CD45hi cells (cells in red-circled areas), (B) CD4/CD8 expression for T cells, and (C) cytokine staining of IL-4 or IFN-g in
T cells are shown.
(D) Numbers of each subset of lymphocytes in the spinal cord from each mouse line are shown.
(E and F) Numbers of each subset of (E) IFN-g- or (F) IL-4-producing lymphocytes in the spinal cord from each mouse line are shown.
(G) Mean ratios of IFN-g/IL-4-producing cells are shown.
(H) Cell numbers per microliter of CD3+ T cells in the peripheral blood of Non-Tg, GFAP-TGF-b1, end-stage G93A, and G93A/TGF-b1 mice are shown. (D–H)
*p < 0.05, **p < 0.01, ***p < 0.001. NS, not significant. Mean ± SEM were plotted (n = 6–7 in D–G and n = 8 in H).We found that TGF-b1 mRNA level was significantly reduced in
loxSOD1G37R/GFAP-Cre+ mice compared with loxSOD1G37R/
GFAP-Cremice (Figure 7E). Furthermore, immunofluorescence
analysis showed that TGF-b1 as well as GFAP expressions were
reduced in the spinal cord astrocytes of loxSOD1G37R/GFAP-
Cre+ mice compared with loxSOD1G37R/GFAP-Cre mice (Fig-
ures 7F and 7G). In summary, astrocytic TGF-b1 is one of the
key factors induced bymutant SOD1 that is linked to accelerated
disease progression in ALS mice.Pharmacological Inhibition of TGF-b Signaling Slows
Disease Progression and Extends Survival of SOD1G93A
Mice
To explore the therapeutic potential of modifying glial TGF-b
signaling and to validate an adverse role of excess TGF-b in
neuroinflammation, we administered TGF-b signaling inhibitor
SB-431542 intraperitoneally to symptomatic SOD1G93A mice.
SB-431542 slowed disease progression and extended survival
time of SOD1G93A mice (Figure 7H). We also examined theCell Reports 11, 592–604, April 28, 2015 ª2015 The Authors 599
Figure 6. Correlation between Decreased Microglial IGF-I/CD11c Expressions and Decreased Number of T Cells with Increased IFN-g/IL-4
Ratio in the Presence of TGF-b1 Overproduction in Astrocytes
Flow cytometric analyses of primarymicroglia from non-transgenic (Non-Tg), SOD1G93A (G93A), and SOD1G93A/TGF-b1 (G93A/TGF-b1)mice and T cells in PBMC
from Non-Tg and end-stage G93A mice in the primary glial and PBMC co-culture assay.
(A) Experimental design for the primary glial and PBMC co-culture assay and flow cytometry is shown.
(B) Flow cytometric analysis shows IGF-I and CD11c for primary microglia cultured with PBMC (black, Non-Tg; blue, G93A; red, G93A/TGF-b1).
(C and D) Plotted relative expression levels of (C) IGF-I and (D) CD11c in primary microglia. Each datum was normalized to that of Non-Tg primary microglia
cultured without PBMC.
(E) Plotted numbers of each subset of T cells and non-T cells in PBMC from Non-Tg, G93A mice cultured with primary glial cells from each mouse line are shown.
(F and G) Plotted numbers of each subset of (F) IFN-g- and (G) IL-4-producing lymphocyte in PBMC from each mouse line are shown.
(H) Plottedmean ratios of IFN-g/IL-4-producing T cells in PBMC from eachmouse line are shown. (C–H) *p < 0.05, **p < 0.01. NS, not significant. Error bars denote
SEM (n = 3).
(I and J) Plotted Spearman correlations between expression level of (I) IGF-I and (J) CD11c in primary microglia and the ratio of IFN-g/IL-4-producing T cells in
PBMC (n = 9, r = 0.8833, and p = 0.0031 in I and n = 9, r = 0.7833, and p = 0.0172 in J) are shown.
See also Figure S5.effect of SB-431542 on the very late symptomatic SOD1G93A
mice (140 days old), revealing a trend toward extension of their
survival times (Figure S6). These results indicate that inhibiting
TGF-b signaling after disease onset ameliorates disease in ALS
mice.600 Cell Reports 11, 592–604, April 28, 2015 ª2015 The AuthorsDISCUSSION
In this study, we have demonstrated that astrocyte-specific
overproduction of TGF-b1 in mutant SOD1 mice results in accel-
erated disease progression in a non-cell-autonomous manner,
Figure 7. Astrocytic TGF-b1 Is a Determinant
for Disease Progression and Survival for ALS
Mice, and TGF-b Signaling Inhibitor Extends
the Survival Time of ALS Mice
(A–C) Correlations between survival time, IFN-g/IL-
4 ratio, and TGF-b1 level in SOD1G93A mice. (A)
Plotted Spearman correlations (A) between TGF-b1
mRNA and the survival time of SOD1G93A mice (n =
14, r = 0.8194, and p = 0.0003), (B) between ratio
of IFN-g/IL-4mRNA and the survival time (n = 10, r =
0.8368, and p = 0.0083), and (C) between TGF-b1
mRNA and ratio of IFN-g/IL-4 mRNA (n = 10, r =
0.7833, and p = 0.0172) are shown.
(D–G) Astrocytic TGF-b1 is downregulated in lox-
SOD1G37R mice with astrocyte-specific deletion of
mutant SOD1. (D) A schematic drawing shows
astrocyte-specific deletion of mutant SOD1 in lox-
SOD1G37R mice using Cre-loxP system, which
leads to slowing the disease progression.
(E) TGF-b1 mRNA levels in the lumbar spinal
cord of end-stage loxSOD1G37R/GFAP-Cre– and
loxSOD1G37R/GFAP-Cre+ mice relative to age-
matched Non-Tg mice are shown. **p < 0.01. Mean
± SEM were plotted (n = 6).
(F) Representative images show the ventral horn of
the lumbar spinal cord of end-stage loxSOD1G37R/
GFAP-Cre– and loxSOD1G37R/GFAP-Cre+ mice
stained for TGF-b1 (green) and GFAP (red), along
with the merged image. Scale bars, 50 mm.
(G) Mean fluorescent intensities of TGF-b1 in the
gray matter of lumbar ventral horn of loxSOD1G37R/
GFAP-Cre+ mice relative to loxSOD1G37R/GFAP-
Cre– mice. *p < 0.05. Error bars denote SEM (n = 3).
(H) Peripheral administration of TGF-b inhibitor
extended the survival time of SOD1G93A mice.
SOD1G93A mice were intraperitoneally injected with
SB-431542 (10 mg/kg, n = 8) or vehicle (DMSO/
PBS, n = 8) five times per week from 16 weeks old
(after disease onset). Kaplan-Meier analysis for the
survival time and plotted mean survival showed that
SB-431542 extended the survival of SOD1G93A
mice (SB-431542: 166.0 ± 8.7 days, vehicle: 156.9
± 6.3 days, log-rank test: p = 0.0168). *p < 0.05.
Error bars denote SD (n = 8, four males and four
females in each group).
See also Figure S6.with reduced neurotrophic factor production in deactivated mi-
croglia/macrophages and an IFN-g-dominant environment of in-
filtrated T cells. Moreover, the lower level of TGF-b1 was
achieved by astrocyte-specific deletion of mutant SOD1 from
ALS mice, which slows disease progression. Furthermore, phar-
macological inhibition of TGF-b signaling in symptomatic ALS
mice extended survival time. These results provide compelling
evidence that astrocytic TGF-b1 inhibits the neuroprotective in-
flammatory responses coordinated by microglia/macrophages
and T cells.
Our study demonstrated elevated TGF-b1 levels in astrocytes
of ALS patients and mice. Although TGF-b signaling has beenCell Reports 11, 592–implicated in the pathogenesis of ALS
(Iida et al., 2011; Phatnani et al., 2013),
the detailed mechanisms are yet to be
elucidated (Katsuno et al., 2011). We demonstrated that
decreased expression of pSmad2 in motor neuron nuclei
occurred at the pre-symptomatic stage and was exacerbated
during disease progression in ALS mice. Moreover, exogenous
expression of TGF-b1 in SOD1G93A mice did not improve
pSmad2 level within motor neuron nuclei, the motor function,
or disease course of mice. In spinobulbar muscular atrophy
(SBMA), an inherited motor neuron disease caused by mutant
androgen receptor, we previously reported a defect of TGF-b
signaling in motor neurons (Katsuno et al., 2010). Intriguingly,
while downregulation of TGFbR2 was observed in SBMA motor
neurons, a defect in nuclear transport of pSmad2 was observed604, April 28, 2015 ª2015 The Authors 601
in SOD1-ALS motor neurons rather than dysregulation of TGF-b
receptors. In addition, dysregulated pSmad2/3 expression has
been observed in motor neuron nuclei of patients with sporadic
ALS (Nakamura et al., 2008). Our results along with these reports
indicate that the dysfunction of TGF-b signaling, especially de-
fects downstream of the TGF-b receptor in motor neurons, is
involved in neurodegeneration in both familial and sporadic ALS.
Previous studies have shown that elimination of functional
T cells in SOD1G93A mice shortens their survival time (Beers
et al., 2008; Chiu et al., 2008). However, what regulates the neu-
roprotective immune response in ALS mice remains unclear. In
this study, we found that TGF-b1, known to inhibit T cell prolifer-
ation and differentiation (Li et al., 2006), regulates the number
and IFN-g/IL-4 balance in T cells both in vivo and in vitro and
that microglia-related molecules were misregulated partly
through altered IFN-g/IL-4 balance. This finding suggests that
TGF-b1 is likely to be one of the regulators responsible for con-
trolling neuroprotective immune responses.
On the other hand, TGF-b1 has been reported to deactivate
microglia (Lodge and Sriram, 1996; Suzumura et al., 1993)
and to regulate antigen-presentation function of microglia
in vitro (Abutbul et al., 2012; Suzumura et al., 1993). The influ-
ence of TGF-b1 on microglia, however, is unclear in the context
of neurodegeneration (Flanders et al., 1998). Our results show
that astrocyte-specific overproduction of TGF-b1 deactivates
microglia/macrophages with reduced expression of Mac-2,
CD68, CD11c, MHC class II, and IGF-I both in vivo and
in vitro. Of note, T cell activation requires expression of MHC
class II in antigen-presenting cells, including microglia and
macrophages. Furthermore, IGF-I+ CD11c+ microglia have
been reported to exert beneficial effects over neurodegenera-
tion (Butovsky et al., 2006; Chiu et al., 2008). Thus, the current
study suggests that astrocytic TGF-b1 inhibits the neuropro-
tective properties of microglia not only indirectly by regulating
the number and balance of IFN-g/IL-4 in T cells, but also
directly through the deactivation of microglial functions,
including antigen presentation. Previous studies have estab-
lished that infiltration and activation of a large number of mac-
rophages occurs in the peripheral nerves of SOD1G93A mice
(Chiu et al., 2009; Kano et al., 2012). In the current study,
reduced expression of IGF-I, CD11c, and CD68 in macro-
phages was observed in the lumbar ventral root of SOD1G93A/
TGF-b1 mice, indicating that the TGF-b1-induced deactivation
of macrophages in the ventral root also contributes to acceler-
ated disease progression.
In addition, TGF-b1 is critical to the development of micro-
glia (Butovsky et al., 2014). Although nuclear pSmad2 was
preserved in both microglia and astrocytes of SOD1G93A
mice, expressions of microglia-related molecules such as
CD68 were significantly reduced compared with those related
to astrocytes in SOD1G93A/TGF-b1 mice. These results impli-
cate that TGF-b1 exhibits more robust effects on microglia
than on astrocytes, likely because expressions of TGF-b re-
ceptors in microglia are highly dependent on TGF-b1 (Butov-
sky et al., 2014).
IGF-I has been found to exhibit neuroprotective properties in
motor neurons. For example, IGF-I enhances axonal outgrowth
of motor neurons, and microglia-derived IGF-I is required for602 Cell Reports 11, 592–604, April 28, 2015 ª2015 The Authorsthe survival of motor and cortical neurons (Ozdinler and Macklis,
2006; Ueno et al., 2013). Moreover, IGF-I administration pro-
longs the survival time of SOD1G93A mice (Dodge et al., 2008;
Kaspar et al., 2003). Thus, in the current study, the marked
reduction of IGF-I in the lumbar spinal cord of SOD1G93A/TGF-
b1 mice might have contributed to an accelerated disease pro-
gression. Although TGF-b1 itself slightly reduces expression
levels of IGF-I, we observed that IFN-g, and not TGF-b1, showed
a strong antagonizing effect on the expression of IGF-I in micro-
glia induced by IL-4 in vitro. Furthermore, IGF-I expression in
microglia was regulated by the IFN-g/IL-4 balance in vitro. We
found that the level of GDNF, a potent survival factor for motor
neurons that prolongs the survival of SOD1G93Amice (Henderson
et al., 1994; Kaspar et al., 2003; Wang et al., 2002), also was
reduced in SOD1G93A/TGF-b1 mice, suggesting that the
neurodegenerative mechanism, similar to IGF-I reduction,
might involve a low level of GDNF in SOD1G93A/TGF-b1 mice.
Together, decreased levels of these neurotrophic factors
through enhanced expression level of TGF-b1 seem to have
important roles in the accelerated disease progression in
SOD1G93A/TGF-b1 mice.
We demonstrated that expression levels of endogenous TGF-
b1 mRNA at the end stage negatively correlates with the survival
time of SOD1G93A mice and positively correlates with the IFN-g/
IL-4 ratio. These findings suggest a functional relationship be-
tween astrocytes producing TGF-b1 and T cells producing
IFN-g/IL-4 in the disease progression, not only in SOD1G93A/
TGF-b1mice but also in SOD1G93A mice. Moreover, the negative
correlation between TGF-b1 level and survival time of ALS mice
is consistent with our observation that astrocyte-specific dele-
tion of mutant SOD1 extended survival time with a lower level
of astrocytic TGF-b1. Our results indicate that astrocytic TGF-
b1 is a determinant of disease progression in ALS mice, and
TGF-b1 shall be evaluated as a candidate biomarker to predict
disease progression of ALS.
Finally, pharmacological administration of TGF-b signaling in-
hibitor SB-431542 after disease onset extended the survival time
of SOD1G93A mice. Though peripherally administered, SB-
431542 was presumably effective in the diseased spinal cord,
since the blood-spinal cord barrier was damaged in the symp-
tomatic mutant SOD1 mice (Zhong et al., 2008). In addition, an
adverse effect on motor neurons by inhibiting TGF-b signaling
is likely to be minimal, since TGF-b signaling in motor neurons
is already defective at the late symptomatic stage. The effect
of a TGF-b1 inhibitor on extension of the survival time might be
more robust if TGF-b signaling in motor neurons would be
simultaneously protected. Nevertheless, our data validated an
adverse role of excess glial TGF-b1 in neuroinflammation and
uncovered the therapeutic potential of modifying glial TGF-b
signaling in ALS.
In conclusion, our study provides evidence that astrocytic
TGF-b1 plays a key role in the neuroprotective inflammatory
response in ALS mice by regulating microglial activation, T cell
number, and IFN-g/IL-4 balance. Our findings suggest that tar-
geting TGF-b signaling in a cell-type-specific manner, such as
restoration of TGF-b signaling in motor neurons and suppressing
excess TGF-b1 in astrocytes, may represent a therapeutic
approach for the treatment of motor neuron diseases.
EXPERIMENTAL PROCEDURES
Detailed information is available in the Supplemental Experimental
Procedures.Postmortem Human Tissues
Specimens of spinal cords from two patients with sporadic ALS and two
other neurological disease patients as controls were obtained by autopsy
with informed consent (Table S1). The diagnosis of ALS was confirmed by
El Escorial diagnostic criteria as defined by the World Federation of
Neurology. The collection of tissues and their use in this study were
approved by the ethics committee of Nagoya University. For immunofluo-
rescence analysis, sections were prepared from formalin-fixed and
paraffin-embedded tissues, deparaffinized, and boiled for 30 min in
50 mM citrate buffer (pH 6.0).Mice
Transgenic mice expressing familial ALS-linked SOD1 mutations, SOD1G93A
(B6.Cg-Tg (SOD1*G93A)1Gur/J, Jackson Laboratory), LoxSOD1G37R (Boille´e
et al., 2006), and SOD1G85R (Bruijn et al., 1997), were described previously.
GFAP-TGF-b1 mice (a low-expressing line [line T64] on a C57BL/6 genetic
background) (Wyss-Coray et al., 1995) and GFAP-Cre mice (Bajenaru et al.,
2002) were described previously. To generate mice heterozygous for both
SOD1G93A and GFAP-TGF-b1 transgenes, SOD1G93A males were bred with
GFAP-TGF-b1 females. To generate loxSOD1G37R mice with astrocyte-spe-
cific deletion of mutant SOD1, loxSOD1G37R males were bred with GFAP-
Cre females. The animal study was approved by the Animal Care and Use
Committee of Nagoya University and RIKEN.Analysis of Disease Progression, Survival, and Motor Function of
Mice
SOD1G93A mice always were compared with their SOD1G93A/TGF-b1 litter-
mates. Disease onset was determined as the time when mice reached
maximum body weight, and the end stage was determined by the inability of
an animal to right itself within 20 s when placed on its side. Definitions for early
and late disease were described previously (Boille´e et al., 2006). The motor
function of mice was tested by an accelerated rotarod task with a rotarod de-
vice (MK-610A, Muromachi Kikai).
See the Supplemental Experimental Procedures for details.Primary Glial Cell and PBMC Co-culture Assay
To isolate PBMCs, blood was collected from the central tail artery of
mice. PBMCs were isolated using Lymphosepar II (IBL) by centrifugation at
400 3 g for 30 min. Then, 5 3 105 PBMCs were cultured in 10% fetal bovine
serum (FBS) RPMI-1640 medium with primary glial cells in 12-well plates for
4 days. For flow cytometric analyses, PBMCs were obtained from the culture
media of this assay, and primary microglia were obtained from adhesive glial
cells after treatment with trypsin-EDTA (Gibco).Flow Cytometry Analyses of Spinal Cord Immune Cells, PBMCs, and
Primary Microglia
Mice were transcardially perfused with PBS. Spinal cords were dissected,
minced into 1-mm3 pieces in collagenase working solution (1 mg/ml Colla-
genase IV [Worthington] and 0.4 mg/ml DNase I [Roche]), and incubated
at 37C for 15 min. For isolation of immune cells and microglia, cells were
re-suspended in 37% Percoll (GE Healthcare) and centrifuged at 780 3 g
for 20 min. After centrifugation, myelin debris was removed and cell pellets
were collected. Cells were then washed twice with PBS and suspended in
10% FBS RPMI-1640 medium or DMEM. Intracellular staining was per-
formed as previously described (Komine et al., 2003) with modifications.
Flow cytometry analyses were performed on FACS Aria and FACS Verse
flow cytometer (Becton Dickinson). The data were analyzed by using FlowJo
Software (Tree Star). Details are described in the Supplemental Experi-
mental Procedures.Administration of TGF-b Signaling Inhibitor In Vivo
SOD1G93A mice were intraperitoneally injected with TGF-b signaling inhibitor
SB-431542 (Sigma, 5 or 10 mg/kg) or vehicle (DMSO/PBS) five times per
week either at 16 weeks old (early symptomatic phase) or 20 weeks old (late
symptomatic phase).
Statistical Analysis
Statistical analyses of survival time and disease duration were performed with
a log-rank test and unpaired t test, respectively. Statistical analysis of the fold
change of relative mRNA levels determined by qRT-PCRwas performed with a
one-way ANOVA followed by Tukey’s test or paired or unpaired t test. All an-
alyses were carried out using GraphPad Prism.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.03.053.
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